1/25
Comprehensive vocabulary flashcards for cardiovascular pharmacology covering heart failure drugs, diuretics, antianginal medications, and lipid-lowering therapies.
Epinephrine
An adrenergic agonist that acts on alpha-1, beta-1, and beta-2 receptors to squeeze vessels, speed up the heart, and open airways; primarily used for anaphylaxis and cardiac arrest.
Dobutamine
An adrenergic agonist that primarily stimulates beta-1 receptors to act as a positive inotrope, making the heart pump harder; primarily used for acute heart failure and cardiogenic shock.
Phentolamine
The injectable antidote administered locally into tissue in the event of adrenergic agonist IV extravasation to prevent tissue necrosis.
Sacubitril/Valsartan (Entresto)
An angiotensin receptor neprilysin inhibitor (ARNI) combination drug that blocks angiotensin II receptors (valsartan) and inhibits neprilysin (sacubitril) to increase BNP levels, reducing fluid overload and cardiac workload in chronic heart failure.
Neprilysin
An endogenous enzyme responsible for breaking down B-type natriuretic peptide (BNP); it is inhibited by sacubitril to prolong BNP activity and promote natriuresis.
Angioedema
A serious, potentially life-threatening swelling of the lips, tongue, and throat that can occur with sacubitril/valsartan; requires waiting at least 36hours after discontinuing an ACE inhibitor before starting an ARNI.
Digoxin
A cardiac glycoside that increases myocardial contractility (positive inotrope) and slows heart rate (negative chronotrope); used to treat heart failure and atrial fibrillation.
Digoxin toxicity
An adverse condition manifested initially by gastrointestinal disturbances (anorexia, nausea, vomiting), progressing to visual changes (blurred vision, yellow-green halos around lights), bradycardia, and dysrhythmias; risk is elevated by hypokalemia.
Digoxin immune fab (DigiFab)
The specific antibody antidote administered to reverse severe, life-threatening digoxin toxicity.
Positive inotrope
A medication property or agent (such as dobutamine or digoxin) that strengthens the force of myocardial contractions.
Negative chronotrope
A medication property or agent (such as digoxin) that slows the heart rate.
Furosemide (Lasix)
A high-ceiling loop diuretic that blocks sodium, potassium, and chloride reabsorption in the loop of Henle; it produces rapid diuresis even in patients with impaired renal function.
Ototoxicity
Damage to the ear causing hearing loss or tinnitus; an adverse effect linked to rapid IV push of furosemide or concurrent use with aminoglycoside antibiotics like gentamicin.
Spironolactone
A potassium-sparing diuretic that blocks aldosterone in the collecting duct of the nephron, prompting the excretion of sodium and water while retaining potassium.
Gynecomastia
Breast enlargement or tenderness in males resulting from the endocrine-modulating adverse effects of spironolactone.
Hydrochlorothiazide (HCTZ)
A medium-strength thiazide diuretic acting on the early distal convoluted tubule to promote sodium and water excretion; indicated as first-line therapy for essential hypertension.
Mannitol
An IV-administered osmotic diuretic that acts as a water magnet to pull fluid from swollen tissues (such as the brain or eye) into the vascular compartment for renal elimination.

Diuretic sites of action in the kidney
The nephron segments targeted by specific diuretic classes: mannitol works in the proximal tubule, furosemide in the loop of Henle, hydrochlorothiazide in the distal tubule, and spironolactone in the collecting duct.
Nitroglycerin
An organic nitrate that produces predominant venodilation, lowering preload and myocardial oxygen demand while also dilating coronary arteries; used to treat and prevent angina.
Nitrate tolerance
The loss of antianginal efficacy occurring with continuous nitrate administration; prevented by implementing a daily nitrate-free interval of 10–12hours.
Ranolazine (Ranexa)
An antianginal agent for chronic stable angina that lowers myocardial oxygen consumption without significantly altering blood pressure or heart rate; carries a notable risk of QT prolongation.
Atorvastatin
An HMG-CoA reductase inhibitor that suppresses hepatic cholesterol synthesis to significantly lower LDL and triglyceride levels, reducing heart attack and stroke risk.
Rhabdomyolysis
A severe adverse complication of statin therapy characterized by muscle breakdown, severe weakness, dark (cola-colored) urine, and potential acute kidney injury.
Ezetimibe (Zetia)
A cholesterol absorption inhibitor that blocks dietary and biliary cholesterol uptake in the small intestine to lower circulating LDL levels.
Colesevelam
A bile-acid sequestrant that binds bile acids in the gastrointestinal tract for fecal elimination, prompting hepatic conversion of cholesterol to bile; may impair absorption of fat-soluble vitamins (A, D, E, K).
Alirocumab (Praluent)
A monoclonal antibody (PCSK9 inhibitor) administered subcutaneously that blocks PCSK9 from degrading hepatic LDL receptors, resulting in increased clearance of LDL from the blood.